In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe

被引：36
|
作者：
Jansen, W. T. A. [1 ]
Verel, A. [1 ]
Verhoef, J. [1 ]
Milatovic, D. [1 ]
机构：
[1] Univ Med Ctr, NL-3584 CX Utrecht, Netherlands
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2007年 / 51卷 / 09期
关键词：
D O I：
10.1128/AAC.00100-07
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The in vitro activity of telavancin was tested against 620 gram-positive isolates. For staphylococci, MICs at which 50 and 90% of isolates were inhibited (MIC50 and MIC90) were both 0.25 mu g/ml, irrespective of methicillin resistance. MIC50 and MIC90 were 0.25 and 0.5 mu g/ml for vancomycin-susceptible enterococci and 1 and 2 mu g/ml for vancomycin-resistant enterococci, respectively. Streptococcus pneumoniae, group A and B beta-hemolytic streptococci, and viridans streptococci were inhibited by <= 0.12 mu g/ml.
引用
收藏
页码：3420 / 3424
页数：5
相关论文
共 50 条
  • [41] Antimicrobial Activity of Telavancin Tested In Vitro Against a Global Collection of Gram-Positive Pathogens, Including Multidrug-Resistant Isolates (2015-2017)
    Duncan, Leonard R.
    Sader, Helio S.
    Huband, Michael D.
    Flamm, Robert K.
    Mendes, Rodrigo E.
    MICROBIAL DRUG RESISTANCE, 2020, 26 (08) : 934 - 943
  • [42] Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015)
    Pfaller, Michael A.
    Suter, Helio S.
    Shortridge, Dee
    Castanheira, Mariana
    Flamm, Robert K.
    Mendes, Rodrigo E.
    JOURNAL OF CHEMOTHERAPY, 2019, 31 (04) : 188 - 194
  • [43] In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates
    Testa, Raymond
    Canton, Rafael
    Giani, Tommaso
    Morosini, Maria-Isabel
    Nichols, Wright W.
    Seifert, Harald
    Stefanik, Danuta
    Rossolini, Gian Maria
    Nordmann, Patrice
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 45 (06) : 641 - 646
  • [44] Comparative In Vitro Activity Profiles of Novel Bis-Indole Antibacterials against Gram-Positive and Gram-Negative Clinical Isolates
    Butler, Michelle M.
    Williams, John D.
    Peet, Norton P.
    Moir, Donald T.
    Panchal, Rekha G.
    Bavari, Sina
    Shinabarger, Dean L.
    Bowlin, Terry L.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (09) : 3974 - 3977
  • [45] In Vitro Activity of Essential Oils Against Gram-Positive and Gram-Negative Clinical Isolates, Including Carbapenem-Resistant Enterobacteriaceae
    Patterson, Jan E.
    McElmeel, Leticia
    Wiederhold, Nathan P.
    OPEN FORUM INFECTIOUS DISEASES, 2019, 6 (12):
  • [46] In vitro activity of the new quinolone moxifloxacin (Bay 12-8039) against resistant gram-positive clinical isolates
    Alcalá, L
    Cercenado, E
    García-Garrote, F
    Bouza, E
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 33 (01) : 27 - 31
  • [47] In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe
    Carvalhaes, Cecilia G.
    Duncan, Leonard R.
    Wang, Wen
    Sader, Helio S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (11)
  • [48] Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates
    Cunha, BA
    Qadri, SMH
    Ueno, Y
    Walters, EA
    Domenico, P
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 : 29 - 34
  • [49] IN-VITRO ACTIVITY OF TROSPECTROMYCIN AGAINST GRAM-POSITIVE COCCI
    BEAM, TR
    GORZYNSKI, EA
    ROTSTEIN, C
    AMSTERDAM, D
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 (05) : 874 - 878
  • [50] Activity of newer fluoroquinolones in vitro against gram-positive bacteria
    Eliopoulos, GM
    DRUGS, 1999, 58 (Suppl 2) : 23 - 28
12345